Key Facts

Invested since 2016
Based in Bavaria

About the company

SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.

Do you want to

know more about this company?

Zum Artikel

Dr. Frank Hensel Principal

Dr. Frank HenselPrincipal

SciRhom in the news

Zum Artikel

Story

27. August 2024

Against the tide – HTGF portfolio SciRhom company rewarded for courage with EUR 63 million Series A financing

Zum Artikel

News

9. July 2024

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.

More startups from Life Sciences